Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Funny thing is, a buyout is really very possible with them. I would not be surprised if somebody does make an offer for them. What manufacturer wouldnt want to make their products better, and keep an obvious competitor out of their way of profits. Just a thought.
Keep on eye on VKNG. Starting to make a nice move! Just an FYI!
Just doing a little digging this am. Came across this. Its a pretty strong list of investors in the company, including Mr. Icahn. If these groups are betting on it sub dollars, imagine the ones that have their eyes on it that are waiting for the pps to rise before buying in.
http://www.quote.com/us/stocks/topholders.action?s=ANX
You really need to learn how to read. I said I just ran accross this story from back in 08 and 09. I asked if anyone knew what happened to turn things around and for them to continue moving forward instead of selling off and closing down. Maybe u need to fire up another bowlie!! lol
Hornett, here is the link to the story I read:
http://www.xconomy.com/san-diego/2008/12/15/adventrx-pharmaceuticals-considers-selling-cancer-drugs/
This is actually dated 12-08, but the other 1 I read was 3-09!! Thanks!
yes, what? Do you know what happened to change their minds to continue? What the heck is moveon.org? thats funny!!
Ill preface this by saying I have 25,000 shares and am long here, at the moment. I was reading some old releases and I saw that in March of last year the company reduced employees, the ceo resigned, and was looking to sell off their drugs that they were working on and close up shop. Does anyone know why or how they turned things around, changed their minds if you will, and continued moving forward to where we are today? The 2 products seem like a game changer for them, but im wondering how this all ties together. I hope its not just fluff to get them a nice severance before they close up shop, 1 last hurrah, which I really hope doesnt occur!! Any info would really help in my DD! TIA
I see that "see my board" comment in alot of your posts. What board is yours? Thanks in advance.
thankyou, and good luck to you as well.
Ken, Im interested in your opinion of NVLT!
Their pIII trial has had to be extended because of the exemplary survival rate of the patients in trial. Add this to the fact that their NOV-002 drug is deemed safe and it actually reduces the toxicity associated with chemotherapy and efficacy is far superior to existing therapies. They have received SPA and fast track status from the FDA and the pIII, although expected to be finished by now, should be completed within the next 90 days.
Though Novelos is blinded to the ongoing study, it doesn't take a rocket scientist to realize that since the 725th event has not yet occurred, well .....
Put simply, the patients are surviving significantly longer than expected. And thank God for that. Not just for their sake but for their families as well.
Do you have an opinion on this company and it's prospects?
should have results within 90 days. gl
Im right there with you. Rode it up from .93 to 2.15, then bought back in at 1.75 and watched it keep dropping to its present levels. Would be nice to see some green again. gl
Ken, cant reply private. Looks like a real nice move today, and interesting business plan. Dont follow this one, but I think they could be in right place at right time, with all the deregulation that has, is, and will be going on in near term. Will keep an eye on this one now! Glty and have a safe and happy holidays.
Have watched this a long time, since about .60! Very strange action, but Im thinking after initial rise and shake this am, we should see this move up some more before the day is through. My guess should be 1.60-1.70 on conservative side. This is very good news, and the company has an impressive pipeline.
AVII news out!!!
BOTHELL, WA--(Marketwire - 12/22/09) - AVI BioPharma, Inc. (NASDAQ:AVII - News), a developer of RNA-based drugs, today announced initial efficacy data from the ongoing Phase 1b/2 clinical trial of AVI-4658 for the systemic treatment of patients with Duchenne muscular dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin. Patients in the first four (of six) cohorts completing 12 weeks of treatment with different doses of AVI-4658 (0.5, 1.0, 2.0 or 4.0 mg/kg) have had their muscles biopsied. Analysis of the post treatment biopsies found that patients in the 2 and 4 mg/kg drug-treatment cohorts (3 of 3 in total) showed correctly spliced mRNA for dystrophin. One of these patients, in the 2mg/kg cohort, showed robust expression of dystrophin protein by western blot and immunofluorescent analysis. No RNA or protein expression signal was detected in patients from the 0.5 mg/kg or 1.0 mg/kg cohorts after completing treatment. Restoration of functional dystrophin expression is considered critical for successful treatment of DMD.
Treatment with AVI-4658 in the three patients in the 2.0 and 4.0 mg/kg cohorts led to accurate skipping of exon 51, which is believed to be necessary to restore the mRNA reading frame for functional dystrophin expression in patients with this class of mutations. Analysis of post-treatment biopsies by the reverse transcription-polymerase chain reaction showed a new lower molecular weight band of RNA resulting from the intended skipping, or exclusion, of exon 51. The intensity of the higher molecular weight band (which included exon 51) was correspondingly reduced. In one of the patients at the 2.0 mg/kg dose, the appearance of skipped mRNA was accompanied by a robust increase in expression of dystrophin protein in the post treatment samples using both western blot and immunofluorescent analysis. Western blot analysis detected a fivefold increase in dystrophin expression, from 0.9% to 5.3% of normal. Immunofluorescent analysis of the muscle biopsies from this patient showed an increase in the percentage of dystrophin positive muscle fibers from 1% pre-treatment to 21% in the post-treatment biopsy. Quantitative intensity analysis of the amount of dystrophin per fiber in patient samples before and after drug treatment showed a sevenfold increase in dystrophin. When compared to the level of dystrophin in normal muscle fibers, the dystrophin content per patient fiber went from 5% pre-treatment to 37% in the post-treatment biopsy.
"I am very encouraged by the evidence of accurate skipping of exon 51 in three treated patients," stated Prof. Francesco Muntoni, Professor of Pediatric Neurology and Head of the Dubowitz Neuromuscular Centre at the UCL Institute of Child Health, London, England and the trial's lead investigator. "These results suggest that we are on the right path towards developing a drug that could play a role in the treatment of DMD. The fact that one patient at the 2 mg/kg dose showed significant expression of dystrophin protein leads us to expect greater levels of dystrophin expression following treatment with the higher doses of 10.0 mg/kg and 20.0 mg/kg of AVI-4658, which are currently underway in the trial."
Clinical Trial Design and Update
Study 28 is a Phase 1b/2 open label, dose-ranging clinical trial assessing the safety, tolerability, pharmacokinetics and exploratory efficacy of AVI-4658 in ambulatory DMD boys between the ages of 5 and 15 years of age who have an error in the gene coding for dystrophin that could be treated by skipping exon 51. Patients are dosed once per week for 12 weeks by intravenous infusion. Nineteen patients have been enrolled in total and assigned to one of six dose cohorts: 0.5, 1.0, 2.0, 4.0, 10.0 or 20.0 mg/kg. After completion of dosing, patients are followed for a further 14 weeks. The primary objective of the trial is to assess the safety of AVI-4658 at these doses over the 26-week duration of the trial.
To date, 9 of 10 patients in the first four cohorts (0.5 through 4.0 mg/kg) have completed dosing. A single patient (in the 4 mg/kg cohort) withdrew from treatment due to DMD-related cardiomyopathy (now stabilized and believed not to be drug related). An additional patient was enrolled at 4 mg/kg but has not yet completed dosing. All 8 patients in the fifth and sixth cohorts, receiving 10 or 20 mg/kg respectively, have initiated dosing.
Data from patients dosed to date demonstrate that AVI-4658 continues to be generally very well tolerated. Adverse events reported to date are mostly mild, unrelated to drug treatment and transient. In the patients who completed dosing, two serious adverse events, both deemed unrelated to AVI-4658, were reported in different patients after they completed their 12-week treatment period and during the 14-week follow-up period.
Studies Towards US IND
AVI has completed a series of 12-week preclinical studies of AVI-4658 under Good Laboratory Practice (GLP) conditions required to open an Investigational New Drug (IND) application in the US. The studies tested doses up to 960 mg/kg in both mdx and wild type mice, and up to 320 mg/kg in non-human primates, both doses being the maximum feasible single doses in these animals. In all cases the PMO was well tolerated at doses equivalent to 80 mg/kg and 110 mg/kg in humans respectively (based on standard allometric scaling), suggesting the potential for a wide therapeutic index.
An additional GLP study of AVI-4225 PMO, to skip exon 23, in the mdx mouse has also been completed, with similar encouraging reports of good tolerability. The histopathology is currently being reviewed but initial reports suggest that the muscles of treated mice show improvement over the 12 weeks of study.
"AVI-4658 continues to demonstrate the good safety profile associated with PMO-based drug candidates. Data from the recently completed series of preclinical studies required to open an IND in the US suggest that this good tolerability is likely to continue at higher doses," stated Stephen B. Shrewsbury, M.D., Senior Vice President and Chief Medical Officer, AVI BioPharma, Inc. "This is critically important given that any DMD drug based on exon skipping is expected to be administered regularly over the entire course of a patient's life."
The clinical trial of AVI-4658 is being conducted in London, UK at the UCL Institute of Child Health / Great Ormond Street Hospital NHS Trust facilities by members of the MDEX Consortium led by Professor Muntoni and by Professor Kate Bushby at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the coordinating center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.
About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with DMD with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing requiring ventilatory support. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time ever, there are promising therapies in or moving into development.
Conference Call
AVI management will hold a conference call to review the initial data from the ongoing Phase 1b/2 clinical trial on Tuesday, December 22, 2009, at 8:30 AM Eastern time (5:30 AM Pacific Time).
Individuals interested in listening to the live conference call may do so by dialing 877-879-6209 toll free within the United States and Canada, or 719-325-4794 for international callers. A replay of the call will be available by dialing 888-203-1112 toll free within the United States and Canada, or 719-457-0820 for international callers. The passcode for the replay is 1823048. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Jun?n, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.
About the MDEX Consortium
The MDEX consortium led by Professor Francesco Muntoni, is a multidisciplinary enterprise to promote translational research into muscular dystrophies, and is formed by the clinical groups of Professor Francesco Muntoni (UCL Institute of Child Health) and Professor Kate Bushby and Professor Volker Straub (Newcastle University), and scientists from Imperial College London (Professor Dominic Wells), UCL Institute of Child Health (Dr. Jennifer Morgan), Royal Holloway University of London (Professor George Dickson), Oxford University (Dr. Matthew Wood) and University of Western Australia (Professor Steve Wilton). In addition, the charities Muscular Dystrophy Campaign (MDC), Action Duchenne and Duchenne Family Support Group also participate in the Consortium. For more information, visit www.mdex.org.uk.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
Contact:
Related Message Boards
Avi Biopharma, Inc.
Sponsored Links
Live Forex Practice Account
Practice Forex Trading in Real Market Conditions with a Free Trial.
www.GFTforex.com
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today.
www.sharebuilder.comEarn From 1.90% to 2.20% Apply Online
With GE Capital Corporation. Not An Offer Of Securities For Sale.
www.geinterestplus.com
Refinance Now at 4.1% Fixed
No hidden fees, 4.1% APR. No obligation. Get 4 free quotes. No SSN req.
MortgageRefinance.LendGo.comTop Stories
Economy's Growth Rate Revised Downward to 2.2% Pace - AP
Stock futures point toward higher open - AP
GOP senator: Democratic health care deals 'sleazy' - AP
OPEC keeps oil supply unchanged - Reuters
ADVERTISEMENT
Tech Ticker Recent Posts
Marc Faber: Avoid the U.S. Disaster, Buy Wheat, Sugar, Natural Gas, and Japan in 2010 - Joe Weisenthal
Japan Still Lacking Sense of Crisis, Says Asia Society's Parker - Heesun Wee
Pay Attention to Natural Gas, Pharma Sectors, Says Money Manager - Heesun Wee
View More
Subscribe to Topics
Top Stories
Add Alert
avii Headlines
Add Alert
See all RSS links
Excellent news!!
BOTHELL, WA--(Marketwire - 12/22/09) - AVI BioPharma, Inc. (NASDAQ:AVII - News), a developer of RNA-based drugs, today announced initial efficacy data from the ongoing Phase 1b/2 clinical trial of AVI-4658 for the systemic treatment of patients with Duchenne muscular dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin. Patients in the first four (of six) cohorts completing 12 weeks of treatment with different doses of AVI-4658 (0.5, 1.0, 2.0 or 4.0 mg/kg) have had their muscles biopsied. Analysis of the post treatment biopsies found that patients in the 2 and 4 mg/kg drug-treatment cohorts (3 of 3 in total) showed correctly spliced mRNA for dystrophin. One of these patients, in the 2mg/kg cohort, showed robust expression of dystrophin protein by western blot and immunofluorescent analysis. No RNA or protein expression signal was detected in patients from the 0.5 mg/kg or 1.0 mg/kg cohorts after completing treatment. Restoration of functional dystrophin expression is considered critical for successful treatment of DMD.
Treatment with AVI-4658 in the three patients in the 2.0 and 4.0 mg/kg cohorts led to accurate skipping of exon 51, which is believed to be necessary to restore the mRNA reading frame for functional dystrophin expression in patients with this class of mutations. Analysis of post-treatment biopsies by the reverse transcription-polymerase chain reaction showed a new lower molecular weight band of RNA resulting from the intended skipping, or exclusion, of exon 51. The intensity of the higher molecular weight band (which included exon 51) was correspondingly reduced. In one of the patients at the 2.0 mg/kg dose, the appearance of skipped mRNA was accompanied by a robust increase in expression of dystrophin protein in the post treatment samples using both western blot and immunofluorescent analysis. Western blot analysis detected a fivefold increase in dystrophin expression, from 0.9% to 5.3% of normal. Immunofluorescent analysis of the muscle biopsies from this patient showed an increase in the percentage of dystrophin positive muscle fibers from 1% pre-treatment to 21% in the post-treatment biopsy. Quantitative intensity analysis of the amount of dystrophin per fiber in patient samples before and after drug treatment showed a sevenfold increase in dystrophin. When compared to the level of dystrophin in normal muscle fibers, the dystrophin content per patient fiber went from 5% pre-treatment to 37% in the post-treatment biopsy.
"I am very encouraged by the evidence of accurate skipping of exon 51 in three treated patients," stated Prof. Francesco Muntoni, Professor of Pediatric Neurology and Head of the Dubowitz Neuromuscular Centre at the UCL Institute of Child Health, London, England and the trial's lead investigator. "These results suggest that we are on the right path towards developing a drug that could play a role in the treatment of DMD. The fact that one patient at the 2 mg/kg dose showed significant expression of dystrophin protein leads us to expect greater levels of dystrophin expression following treatment with the higher doses of 10.0 mg/kg and 20.0 mg/kg of AVI-4658, which are currently underway in the trial."
Clinical Trial Design and Update
Study 28 is a Phase 1b/2 open label, dose-ranging clinical trial assessing the safety, tolerability, pharmacokinetics and exploratory efficacy of AVI-4658 in ambulatory DMD boys between the ages of 5 and 15 years of age who have an error in the gene coding for dystrophin that could be treated by skipping exon 51. Patients are dosed once per week for 12 weeks by intravenous infusion. Nineteen patients have been enrolled in total and assigned to one of six dose cohorts: 0.5, 1.0, 2.0, 4.0, 10.0 or 20.0 mg/kg. After completion of dosing, patients are followed for a further 14 weeks. The primary objective of the trial is to assess the safety of AVI-4658 at these doses over the 26-week duration of the trial.
To date, 9 of 10 patients in the first four cohorts (0.5 through 4.0 mg/kg) have completed dosing. A single patient (in the 4 mg/kg cohort) withdrew from treatment due to DMD-related cardiomyopathy (now stabilized and believed not to be drug related). An additional patient was enrolled at 4 mg/kg but has not yet completed dosing. All 8 patients in the fifth and sixth cohorts, receiving 10 or 20 mg/kg respectively, have initiated dosing.
Data from patients dosed to date demonstrate that AVI-4658 continues to be generally very well tolerated. Adverse events reported to date are mostly mild, unrelated to drug treatment and transient. In the patients who completed dosing, two serious adverse events, both deemed unrelated to AVI-4658, were reported in different patients after they completed their 12-week treatment period and during the 14-week follow-up period.
Studies Towards US IND
AVI has completed a series of 12-week preclinical studies of AVI-4658 under Good Laboratory Practice (GLP) conditions required to open an Investigational New Drug (IND) application in the US. The studies tested doses up to 960 mg/kg in both mdx and wild type mice, and up to 320 mg/kg in non-human primates, both doses being the maximum feasible single doses in these animals. In all cases the PMO was well tolerated at doses equivalent to 80 mg/kg and 110 mg/kg in humans respectively (based on standard allometric scaling), suggesting the potential for a wide therapeutic index.
An additional GLP study of AVI-4225 PMO, to skip exon 23, in the mdx mouse has also been completed, with similar encouraging reports of good tolerability. The histopathology is currently being reviewed but initial reports suggest that the muscles of treated mice show improvement over the 12 weeks of study.
"AVI-4658 continues to demonstrate the good safety profile associated with PMO-based drug candidates. Data from the recently completed series of preclinical studies required to open an IND in the US suggest that this good tolerability is likely to continue at higher doses," stated Stephen B. Shrewsbury, M.D., Senior Vice President and Chief Medical Officer, AVI BioPharma, Inc. "This is critically important given that any DMD drug based on exon skipping is expected to be administered regularly over the entire course of a patient's life."
The clinical trial of AVI-4658 is being conducted in London, UK at the UCL Institute of Child Health / Great Ormond Street Hospital NHS Trust facilities by members of the MDEX Consortium led by Professor Muntoni and by Professor Kate Bushby at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the coordinating center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.
About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with DMD with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing requiring ventilatory support. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time ever, there are promising therapies in or moving into development.
Conference Call
AVI management will hold a conference call to review the initial data from the ongoing Phase 1b/2 clinical trial on Tuesday, December 22, 2009, at 8:30 AM Eastern time (5:30 AM Pacific Time).
Individuals interested in listening to the live conference call may do so by dialing 877-879-6209 toll free within the United States and Canada, or 719-325-4794 for international callers. A replay of the call will be available by dialing 888-203-1112 toll free within the United States and Canada, or 719-457-0820 for international callers. The passcode for the replay is 1823048. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Jun?n, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.
About the MDEX Consortium
The MDEX consortium led by Professor Francesco Muntoni, is a multidisciplinary enterprise to promote translational research into muscular dystrophies, and is formed by the clinical groups of Professor Francesco Muntoni (UCL Institute of Child Health) and Professor Kate Bushby and Professor Volker Straub (Newcastle University), and scientists from Imperial College London (Professor Dominic Wells), UCL Institute of Child Health (Dr. Jennifer Morgan), Royal Holloway University of London (Professor George Dickson), Oxford University (Dr. Matthew Wood) and University of Western Australia (Professor Steve Wilton). In addition, the charities Muscular Dystrophy Campaign (MDC), Action Duchenne and Duchenne Family Support Group also participate in the Consortium. For more information, visit www.mdex.org.uk.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
Contact:
Related Message Boards
Avi Biopharma, Inc.
Sponsored Links
Live Forex Practice Account
Practice Forex Trading in Real Market Conditions with a Free Trial.
www.GFTforex.com
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today.
www.sharebuilder.comEarn From 1.90% to 2.20% Apply Online
With GE Capital Corporation. Not An Offer Of Securities For Sale.
www.geinterestplus.com
Refinance Now at 4.1% Fixed
No hidden fees, 4.1% APR. No obligation. Get 4 free quotes. No SSN req.
MortgageRefinance.LendGo.comTop Stories
Economy's Growth Rate Revised Downward to 2.2% Pace - AP
Stock futures point toward higher open - AP
GOP senator: Democratic health care deals 'sleazy' - AP
OPEC keeps oil supply unchanged - Reuters
ADVERTISEMENT
Tech Ticker Recent Posts
Marc Faber: Avoid the U.S. Disaster, Buy Wheat, Sugar, Natural Gas, and Japan in 2010 - Joe Weisenthal
Japan Still Lacking Sense of Crisis, Says Asia Society's Parker - Heesun Wee
Pay Attention to Natural Gas, Pharma Sectors, Says Money Manager - Heesun Wee
View More
Subscribe to Topics
Top Stories
Add Alert
avii Headlines
Add Alert
See all RSS links
awesome. A liitle christmas gift for us, I hope! Come on avii!!
Since I dont subscribe to the site, I cant go on sheffs board and post. Can someone post to sheff and get his thoughts on mcln. Does he still have faith in it, recent events, future, etc. Thanks
People, remove your stop losses as we climb, dont give them a reason to take it down to stop you out. They will do what they can to keep it low, and with a stop loss in, they will try to drop it down to your stop loss if possible to keep it from running. JMHO
Date: Wednesday, December 09, 2009 10:49:39 AM
In reply to: $heff who wrote msg# 20125 Post # of 20171
-MCLN-Goldman Small Cap Research Initiates Coverage on MedClean Technologies (OTCBB: MCLN) With Speculative Buy Rating
PPS:.0325 (+18%)
LOS ANGELES, CA--(Marketwire - 12/09/09) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that former Piper Jaffray's Technology analyst Rob Goldman, who brings over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager, has initiated coverage on MedClean Technologies Inc. (OTC.BB:MCLN - News).
In his report (available as a download to members of BioMedReports) Goldman gives the stock a near-term target of $0.14 and an early 2010 price target of $0.40.
During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology research team covering Israeli Technology and Communications Software. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group as well as the Firm's Israeli research team. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
The coverage report is available now at BioMedReports.Com:
http://biomedreports.com/articles/subscriber-only-content/21414-goldman-small-cap-research-covers-medclean-otcmcln.html
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
just take a look on shefs board. you dont see the panick, the bashing, or nothing like you see here. he is very good at dd'ing a company, and i believe we will be fine with this play. sit back, relax, and buy some more when it dips, you will thank him soon!!
stop selling period. you gotta be an idiot to be selling anyway. if you want to see the price go up and make money, you dont sell, PERIOD!! Hold your shares and make them have to cover. people complain about the pps, but yet they sell at the bid, and worse, shouldnt even be selling at all. give it time to build, and you will be rewarded! jmo
180k traded today!!
Does someone really want to buy this pos stock after what they did to most of us. Havent heard a word from the company in months, they dont answer emails or the phone, and havent seen a word mentioned about this company on any board or discussion group. The product they pumped sounded really good, but I think that was all it was. A real nice piece of bs information to go along with the money they paid a few pumper groups, small cap society to name 1, to put some money in their pockets. Gimme a real post when this is back to .15 cents. They should all be put in jail for that crap!!
Want to apologize to the board for my earlier vulgar comment. Im just getting tired of the BS on here the last few days. The board is here for those invested here to talk about the stock. Too many idiots have since started posting there 2 cents worth, which really doesnt amount to diddly squat. If they want to post a negative comment, thats fine. But to continually post over and over and the bashing is ridiculous. Sheffs board does it right, and now i can see why he doesnt bother to post much here. Too many people with too many agendas. To those of you who have been here and do the right thing, I apologize. I also appreciate your DD. To those idiots showing up here to bash and cause trouble, Take a hike. Take your negativity elsewhere. There are plenty other boards to go to. Maybe even start your own, and you can bash each other!
Posted by: gambinilive Date: Friday, December 04, 2009 12:23:36 PM
In reply to: None Post # of 5660
Can we stop with all the kaboom and to the moon stuff. No one wants to sift thru hundreds of messages of that crap to read something worth while. We can all see it going up or down, so please knock it off. Why do you think shefs board does so well? They dont spout off every 2 seconds. If you have an enlightening post, please share it. If not, we dont need all the bs. The stock wil be fine without it! Thanks.
lets se how long before it gets removed
not in the normal sense. Just making a point that we went up to .58, and then back down to these paltry levels.
Made a nice move early, but then took a massive dump. profit taking for the weekend?
Can we stop with all the kaboom and to the moon stuff. No one wants to sift thru hundreds of messages of that crap to read something worth while. We can all see it going up or down, so please knock it off. Why do you think shefs board does so well? They dont spout off every 2 seconds. If you have an enlightening post, please share it. If not, we dont need all the bs. The stock wil be fine without it! Thanks.
Good news!
PR Newswire "US Press Releases "
BETHEL, Conn., Dec. 4 /PRNewswire-FirstCall/ -- MedClean Technologies, Inc. (OTC Bulletin Board: MCLN) today announced the Company has entered into a preferred stock purchase agreement with Socius Capital Group, LLC, a Delaware limited liability company, doing business as Socius Life Sciences Capital Group, LLC. Pursuant to the Purchase Agreement, MedClean will receive up to $7.5 million in capital.
The Company agreed to sell up to 750 shares of its Series C Preferred Stock, in one or more tranches from time to time. The tranches will be sold at the Company's sole discretion, at a purchase price of $10,000 per share, for an aggregate purchase price of up to $7.5 million. With each tranche, Socius will also receive five-year warrants to purchase that number of shares of the Company's common stock equal to 135% of the value of preferred stock delivered in such tranche. The exercise price of such warrants will equal the closing bid price of the Company's common stock on the date the Company provides notice of such tranche.
Pursuant to the Purchase Agreement MedClean will pay a commitment fee to Socius equal to 5% of the total commitment and will use its best efforts to file a registration statement within 30 days with the Securities and Exchange Commission for the resale of all shares of common stock issuable pursuant to the Purchase Agreement.
Scott Grisanti, the Company's Chairman, commented, "This transaction provides MedClean with the capital required to accelerate execution of its growth and expansion strategy. The Company has claimed the leadership role in industry through development and delivery of its MedClean On-Demand Container and Mobile solutions, which are based on significant intellectual property. The Socius investment vehicle provides the means to expand delivery of MedClean's solutions to a broader customer base through a variety of system acquisition options and additional distribution channels and partners. Also, the investment will enable MedClean to accelerate development plans for new product lines that target new market segments, especially the non-hospital small quantity generator market for regulated medical waste treatment."
David Laky, MedClean's President and CEO commented, "The company's environmentally friendly technology for regulated medical waste disposal and confidential document destruction represents a compelling opportunity for large and small hospitals and medical centers, particularly in light of the current administration's health care cost-cutting focus and escalating concerns by the justice department indicating the need for alternate solutions for medical waste disposal."
About MedClean Technologies, Inc.
MedClean Technologies, Inc. is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste. MedClean's flagship MedClean® Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. MedClean was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further information on MedClean can be found at http://www.medcleantechnologies.com and in filings with the Securities and Exchange Commission found at http://www.sec.gov.
Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2008, filed with the SEC on March 24, 2009, and other filings with the SEC, and is subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
dude, what do you do, go to every board that the stock is down a little and put your 2 cents in. Its not worth 100th of 2 cents, so take a walk. If you cant see the potential in this company, you are an idiot!
Are u kidding me? What the hell are you talking about? Go back from where you came from. Theres no comparison between the the 2.
sqnm news out!
Posted by: daveyjones22 Date: Wednesday, December 02, 2009 3:32:23 PM
In reply to: daveyjones22 who wrote msg# 460 Post # of 461
cs analysis just posted. Sequenom Inc. (Nasdaq: SQNM) is seeing interest late in the session on positive chatter related to research and development news on its Trisomy 21 (Down syndrome) test. Shares up 8.7% in afternoon action.
Did I miss some news? Making a nice run today!
if you read my last post, my friends wife who lives in linden NJ, and works for the big pharmaceutical co. there, said the word around their facility is that they are interested in sequenoms technology, along with at least 1 more co. If that is true, and sqnm is bought out, it will be for a lot more than this piddly 4 or 5 bucks it is now. He also said the data is 95% believed to be accurate and that some info was not not properly handled, not that the test data was faked. They want to be 100% sure, so they are working to get it taken care of. Either sqnm or the company that buys or partners with them will stand to make a butload!! Take it for what its worth, but we have been friends for 20 years, and I was very grateful that he let me in on that bit of news. I have been with sqnm for 5 years or so, and been thru the ringer with them, and now it will soon be time to get paid!!
EOM
This news just hit my inbox:
XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.
“As one of the largest and most well-respected nonprofit organizations dedicated to arthritis research and public health education, the Arthritis Foundation is on an important mission to improve the quality of life for millions of people around the world suffering from more than 100 different types of arthritis,” explained Frank Rizzo, President of XenaCare Holdings. “We are honored to be associated with the Arthritis Foundation as a national sponsor and we look forward to continuing to work closely with the Organization to help support their ongoing efforts,” he added.
With the sponsorship of the Arthritis Foundation, Cobroxin may bear the Arthritis Foundation Proud Sponsor Logo on its packaging. This logo illustrates to consumers that Cobroxin is proud to support the Arthritis Foundation's efforts to help people take control of arthritis. Additionally, the Arthritis Foundation will work with XenaCare and other Proud Sponsors to help build awareness about Cobroxin through its magazine, Arthritis Today, its membership e-newsletter and on its website, Arthritis.org.
The National Proud Sponsor program represents the highest level of collaboration with the Arthritis Foundation. According to the Arthritis Foundation, Proud Sponsors provide critical support of the Foundation's key mission areas including:
Advocacy - Local, state and national efforts to advance vital legislation.
Research - Cutting edge, peer-reviewed research that has the greatest potential for advancement in the search for a cure.
Public health - Information and empowering programs and services.
Community-based outreach - Network of 42 chapter offices
Additional National Proud Sponsors include Wyeth, Abbott, Nature Made® TripleFlex™, Genentech, Bristol-Myers Squibb and Osteo Bi-Flex.
In 2009, XenaCare received the exclusive license from biotechnology company, Nutra Pharma Corporation (OTCBB: NPHC), to market and distribute Cobroxin throughout the United States. Cobroxin is clinically proven to treat moderate to severe (Stage 2) chronic pain and is currently available for sale at several retailers, including online at Cobroxin.com.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States.
In 2009, the Company received the exclusive license to market and distribute Cobroxin within the United States. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) pain. The drug, which recently won the award for “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference held in Miami, Florida, is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.
Benefits to Cobroxin include:
All Natural
Non-Addictive
Non-Narcotic
Non-Opiate
More Potent than Morphine
Long Lasting
The Company’s additional clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. The Company also offers formulations for the lifestyle performance market, which consists of sports line for athletes, including the SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays.
http://www.XenaCareHoldings.com
http://www.Cobroxin.com
Hold tight, it will be there sooner than u think. Just spoke to my buddy in Linden, NJ, whose wife works for the big pharmaceutical co. there, wont name names, and he said the word is there are 2 big pharmas ready to buy sqnm and their technology. If this is true, and she really has heard that, the share price will definately move well past that 5.00. Lets hope this is the leak thats causing this price to go wild!! Keep your fingers crossed.
lol. thats obvious, but its been dead for awhile, and wondered if anything was going on that i didnt catch! Thats a nice move for sqnm with all things considered. would be great if they come back and say the tests are good. shorts would be dead in the water!
SQNM is up 25% today. Anyone know whats happening here? Short covering or possible news leak? Would appreciate any info you have. Thanks.
we're up 25% to 3.97. Whats going on, a short squeeze or a leak of good things coming?